100 related articles for article (PubMed ID: 1815969)
1. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.
Gascon MP; Dayer P
Eur J Clin Pharmacol; 1991; 41(6):573-8. PubMed ID: 1815969
[TBL] [Abstract][Full Text] [Related]
2. [Drug interactions of midazolam].
Gascon MP; Dayer P; Waldvogel F
Schweiz Med Wochenschr; 1989 Dec; 119(50):1834-6. PubMed ID: 2609139
[TBL] [Abstract][Full Text] [Related]
3. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Wang JS; Wen X; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Oct; 85(4):157-61. PubMed ID: 10563513
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes.
Marre F; Fabre G; Lacarelle B; Bourrie M; Catalin J; Berger Y; Rahmani R; Cano JP
Drug Metab Dispos; 1992; 20(2):316-21. PubMed ID: 1352227
[TBL] [Abstract][Full Text] [Related]
5. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
6. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
9. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
[TBL] [Abstract][Full Text] [Related]
11. Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Kosugi Y; Takahashi J
Xenobiotica; 2015 Apr; 45(4):345-52. PubMed ID: 25387130
[TBL] [Abstract][Full Text] [Related]
12. Atmospheric pressure desorption/ionization on silicon ion trap mass spectrometry applied to the quantitation of midazolam in rat plasma and determination of midazolam 1'-hydroxylation kinetics in human liver microsomes.
Steenwyk RC; Hutzler JM; Sams J; Shen Z; Siuzdak G
Rapid Commun Mass Spectrom; 2006; 20(24):3717-22. PubMed ID: 17117443
[TBL] [Abstract][Full Text] [Related]
13. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
14. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
[TBL] [Abstract][Full Text] [Related]
15. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
16. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats.
Suzuki T; Narimatsu S; Fujita S; Masubuchi Y; Umeda S; Imaoka S; Funae Y
Drug Metab Dispos; 1992; 20(3):367-73. PubMed ID: 1355709
[TBL] [Abstract][Full Text] [Related]
19. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
20. In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone.
Surapaneni SS; Clay MP; Spangle LA; Paschal JW; Lindstrom TD
Drug Metab Dispos; 1997 Dec; 25(12):1383-8. PubMed ID: 9394028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
